Not logged in Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial Shore, Neal D.; Gleave, Martin; De Giorgi, Ugo; Rannikko, Antti; Pieczonka, Christopher M.; Sridharan, Swetha; Brasso, Klaus; Woo, Henry H.; Gomez Caamano, Antonio; Saranchuk, Jeff W.; Nordquist, Luke T.; Ferreira, Ubirajara; Tang, Yiyun; Rosbrook, Brad; Haas, Gabriel P.; Rosales, Matt; Zohren, Fabian; Tarazi, Jamal; Freedland, Stephen J. Share Save
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer Shore, Neal D.; Luz, Murilo de Almeida; De Giorgi, Ugo; Gleave, Martin; Gotto, Geoffrey T.; Pieczonka, Christopher M.; Haas, Gabriel P.; Kim, Choung-Soo; Ramirez-Backhaus, Miguel; Rannikko, Antti; Kalac, Matko; Sridharan, Swetha; Rosales, Matt; Tang, Yiyun; Tutrone Jr, Ronald F.; Venugopal, Balaji; Villers, Arnauld; Woo, Henry H.; Wang, Fong; Freedland, Stephen J. Share Save
Share Save
Share Save
Share Save
HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES Sharifi, Nima; Azad, Arun A.; Patel, Mona; Hearn, Jason W. D.; Wozniak, Michele; Zohren, Fabian; Sugg, Jennifer; Haas, Gabriel P.; Stenzl, Arnulf; Armstrong, Andrew J. Share Save
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis Gomez-Veiga, Francisco; Szmulewitz, Russell Z.; Holzbeierlein, Jeffrey; Azad, Arun A.; Iguchi, Taro; Villers, Arnauld; Alcaraz, Antonio; Alekseev, Boris; Shore, Neal D.; Rosbrook, Brad; Zohren, Fabian; Ma, Jie; Haas, Gabriel P.; Stenzl, Arnulf; Armstrong, Andrew J. Share Save
Share Save
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer Freedland, Stephen J.; Luz, Murilo de Almeida; De Giorgi, Ugo; Gleave, Martin; Gotto, Geoffrey T.; Pieczonka, Christopher M.; Haas, Gabriel P.; Kim, Choung-Soo; Ramirez-Backhaus, Miguel; Rannikko, Antti; Tarazi, Jamal; Sridharan, Swetha; Sugg, Jennifer; Tang, Yiyun; Tutrone, Ronald F.; Venugopal, Balaji; Villers, Arnauld; Woo, Henry H.; Zohren, Fabian; Shore, Neal D. Share Save
Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints De Giorgi, U. F. F.; Freedland, S. J.; Gleave, M. E.; Tutrone, R.; Bailen, J. L.; Roos, E.; Kliment, J.; Marx, G. M.; Karsh, L. I.; Ramirez-Backhaus, M.; Uchio, E.; Supiot, S.; Tang, Y.; Rosbrook, B.; Haas, G. P.; Rosales, M.; Zohren, F.; Shore, N. D. Share Save
Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK Freedland, S. J.; Gleave, M. E.; De Giorgi, U. F. F.; Rannikko, A.; Pieczonka, C.; Sridharan, S.; Brasso, K.; Woo, H.; Caamano, A. Gomez; Saranchuk, J.; Nordquist, L. T.; Ferreira, U.; Tang, Y.; Rosbrook, B.; Haas, G. P.; Rosales, M.; Zohren, F.; Shore, N. D. Share Save
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES Armstrong, Andrew J.; Iguchi, Taro; Azad, Arun A.; Villers, Arnauld; Alekseev, Boris; Petrylak, Daniel P.; Szmulewitz, Russell Z.; Alcaraz, Antonio; Shore, Neal D.; Holzbeierlein, Jeffrey; Gomez-Veiga, Francisco; Rosbrook, Brad; Zohren, Fabian; Haas, Gabriel P.; Gourgiotti, Georgia; El-Chaar, Nader; Stenzl, Arnulf Share Save
Share Save
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (Oct, 10.1038/s41391-021-00465-7, 2021) Penson, David F.; Armstrong, Andrew J.; Concepcion, Raoul S.; Agarwal, Neeraj; Olsson, Carl A.; Karsh, Lawrence I.; Dunshee, Curtis J.; Duggan, William; Shen, Qi; Sugg, Jennifer; Haas, Gabriel P.; Higano, Celestia S. Share Save
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial Penson, David F.; Armstrong, Andrew J.; Concepcion, Raoul S.; Agarwal, Neeraj; Olsson, Carl A.; Karsh, Lawrence, I; Dunshee, Curtis J.; Duggan, William; Shen, Qi; Sugg, Jennifer; Haas, Gabriel P.; Higano, Celestia S. Share Save
Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) Armstrong, A. J.; Iguchi, T.; Azad, A. A.; Szmulewitz, R. Z.; Holzbeierlein, J.; Villers, A.; Alcaraz, A.; Alekseev, B. Y.; Shore, N. D.; Petrylak, D. P.; Rosbrook, B.; Zohren, F.; Yamada, S.; Haas, G. P.; Stenzl, A. Share Save
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk Azad, Arun A.; Armstrong, Andrew J.; Alcaraz, Antonio; Szmulewitz, Russell Z.; Petrylak, Daniel P.; Holzbeierlein, Jeffrey; Villers, Arnauld; Alekseev, Boris; Iguchi, Taro; Shore, Neal D.; Gomez-Veiga, Francisco; Rosbrook, Brad; Lee, Ho-Jin; Haas, Gabriel P.; Stenzl, Arnulf Share Save
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses Armstrong, Andrew J.; Shore, Neal D.; Szmulewitz, Russell Z.; Petrylak, Daniel P.; Holzbeierlein, Jeffrey; Villers, Arnauld; Azad, Arun; Alcaraz, Antonio; Alekseev, Boris; Iguchi, Taro; Gomez-Veiga, Francisco; Rosbrook, Brad; Lee, Ho-Jin; Haas, Gabriel P.; Stenzl, Arnulf Share Save
ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels Alcaraz, A.; Szmulewitz, R. Z.; Shore, N.; Crawford, E. D.; Petrylak, D. P.; Holzbeierlein, J.; Villers, A.; Azad, A. A.; Alekseev, B.; Iguchi, T.; Gomez-Veiga, F.; Rosbrook, B.; Sugg, J.; Haas, G. P.; Stenzl, A.; Armstrong, A. J. Share Save
A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status De Giorgi, U.; Shore, N.; Sridharan, S.; Gleave, M.; Rosbrook, B.; Shen, Q.; Sugg, J.; Haas, G. P.; Freedland, S. J. Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI
.png){kind=icon}
Share.png){kind=icon}
Save